Atara Biotherapeutics, Inc.

The current price of ATRA is 0.71 USD — it has increased by 4.89% in the past 24 hours.

Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Atara Biotherapeutics, Inc. stocks are traded under the ticker ATRA.

Atara Biotherapeutics, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.

One year price forecast for Atara Biotherapeutics, Inc. has a max estimate of 13.00 USD and a min estimate of 0.50 USD.

ATRA earnings for the last quarter are −0.66 USD whereas the estimation was −0.62 USD which accounts for −5.98% surprise. Estimated earnings for the next quarter are −0.45 USD. See more details about Atara Biotherapeutics, Inc. earnings.

Yes, you can track Atara Biotherapeutics, Inc. financials in yearly and quarterly reports right on TradingView.

ATRA stock has fallen by 2.07% compared to the previous week, the month change is a 12.60% rise, over the last year Atara Biotherapeutics, Inc. has showed a 76.64% decrease.

Like other stocks, ATRA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Atara Biotherapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.

ATRA reached its all-time high on Jul 14, 2015 with the price of 65.56 USD, and its all-time low was 0.20 USD and was reached on Nov 13, 2023.
See other stocks reaching their highest and lowest prices.

As of Apr 18, 2024, the company has 225.00 employees. See our rating of the largest employees — is Atara Biotherapeutics, Inc. on this list?

EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Atara Biotherapeutics, Inc. EBITDA is ‪−258.62 M‬ USD, and current EBITDA margin is ‪−3.08 K‬%. See more stats in Atara Biotherapeutics, Inc. financial statements.